Yasuhiro Arakawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yasuhiro Arakawa has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Yves Pommier
National Cancer Institute 2 Bethesda, Md
130 shared publications - Suresh Kumar
National Cancer Institute 1 Developmental Therapeutics Branch, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
113 shared publications - Naoko Takebe
National Cancer Institute 2 Division of Cancer Treatment and Diagnosis National Institutes of Health, Bethesda, Maryland
111 shared publications - Ukhyun Jo
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
111 shared publications - Craig J. Thomas
National Institutes of Health
69 shared publications - Jaydira Del Rivero
Developmental Therapeutics Branch, National Cancer Institute, Bethesda, MD 20892, USA
69 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
Combination Therapy with AKT and MEK Inhibitors is Effective in Patient-Derived Models of Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare, aggressive, chemoresistant malignancy with limited effective systemic therapies and few recurrent actionable oncogenic drivers. Although IGF-2 is overexpressed in approximately 80% of ACCs, clinical inhibition of the IGF-1R/InsR axis has not improved outcomes. To identify clinically tractable combination strategies that enhance IGF-1R/InsR inhibition in ACC, we performed a quantitative high-throughput combinatorial screen of 2,803 mechanistically annotated oncology compounds with the IGF 1R/InsR inhibitor linsitinib in an ACC cell line. Downstream effects of IGF-1R/InsR signaling were assessed to identify actionable nodes for combination targeting. Candidate combinations were validated using short-term ACC patient-derived organoids (PDOs) and patient-derived xenograft (PDX) models. The screen identified MAPK pathway inhibitors—particularly MEK inhibition—as the top synergistic partners with IGF-1R/InsR inhibition. Genetic or pharmacologic inhibition of IGF-1R/InsR and MEK signaling suppressed ACC growth in vitro. Downstream profiling of IGF-1R/InsR signaling identified AKT as a major effector, supporting direct AKT targeting as a translatable substitute for IGF-1R/InsR inhibition in ACC. Accordingly, the AKT inhibitor capivasertib synergized with the MEK inhibitor cobimetinib in ACC cell lines and six ACC PDO models. In vivo, combined AKT and MEK inhibition reduced tumor growth more than either agent alone in an ACC xenograft and two ACC chemotherapy-resistant PDX models with acceptable tolerability. These data identify AKT as a critical survival pathway in ACC and support combined AKT and MEK inhibition with FDA-approved agents as a therapeutic approach for chemotherapy-resistant ACC.
- 5 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
Open AccessCombination Therapy with AKT and MEK Inhibitors is Effective in Patient-Derived Models of Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare, aggressive, chemoresistant malignancy with limited effective systemic therapies and few recurrent actionable oncogenic drivers. Although IGF-2 is overexpressed in approximately 80% of ACCs, clinical inhibition of the IGF-1R/InsR axis has not improved outcomes. To identify clinically tractable combination strategies that enhance IGF-1R/InsR inhibition in ACC, we performed a quantitative high-throughput combinatorial screen of 2,803 mechanistically annotated oncology compounds with the IGF 1R/InsR inhibitor linsitinib in an ACC cell line. Downstream effects of IGF-1R/InsR signaling were assessed to identify actionable nodes for combination targeting. Candidate combinations were validated using short-term ACC patient-derived organoids (PDOs) and patient-derived xenograft (PDX) models. The screen identified MAPK pathway inhibitors—particularly MEK inhibition—as the top synergistic partners with IGF-1R/InsR inhibition. Genetic or pharmacologic inhibition of IGF-1R/InsR and MEK signaling suppressed ACC growth in vitro. Downstream profiling of IGF-1R/InsR signaling identified AKT as a major effector, supporting direct AKT targeting as a translatable substitute for IGF-1R/InsR inhibition in ACC. Accordingly, the AKT inhibitor capivasertib synergized with the MEK inhibitor cobimetinib in ACC cell lines and six ACC PDO models. In vivo, combined AKT and MEK inhibition reduced tumor growth more than either agent alone in an ACC xenograft and two ACC chemotherapy-resistant PDX models with acceptable tolerability. These data identify AKT as a critical survival pathway in ACC and support combined AKT and MEK inhibition with FDA-approved agents as a therapeutic approach for chemotherapy-resistant ACC.
- Open Access
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 8 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
Prediction of the efficacy of BTZ-based therapy based on SLFN11 expression in the HOVON-65/GMMG-HD4 clinical trial. EFS was analyzed in 327 newly diagnosed patients with multiple myeloma enrolled in the phase III HOVON-65/GMMG-HD4 trial with available pretreatment gene expression data (PAD, n = 169; VAD, n = 158; refs. 30, 31). Patients were dichotomized into SLFN11-high and SLFN11-low groups at the cohort median (probe 226743_at, log2 = 8.12). A and B, Kaplan–Meier analyses with unadjusted log-rank tests; (C) ISS stage–adjusted Cox regression, excluding patients with unknown ISS stage (n = 23). A, EFS in the VAD arm (without BTZ). B, EFS in the PAD arm (with BTZ). C, ISS stage–adjusted hazard ratios (HR) for PAD vs. VAD by SLFN11 group. Survival data were obtained from the GESTURE repository (48).
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 8 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
Prediction of the efficacy of BTZ-based therapy based on SLFN11 expression in the HOVON-65/GMMG-HD4 clinical trial. EFS was analyzed in 327 newly diagnosed patients with multiple myeloma enrolled in the phase III HOVON-65/GMMG-HD4 trial with available pretreatment gene expression data (PAD, n = 169; VAD, n = 158; refs. 30, 31). Patients were dichotomized into SLFN11-high and SLFN11-low groups at the cohort median (probe 226743_at, log2 = 8.12). A and B, Kaplan–Meier analyses with unadjusted log-rank tests; (C) ISS stage–adjusted Cox regression, excluding patients with unknown ISS stage (n = 23). A, EFS in the VAD arm (without BTZ). B, EFS in the PAD arm (with BTZ). C, ISS stage–adjusted hazard ratios (HR) for PAD vs. VAD by SLFN11 group. Survival data were obtained from the GESTURE repository (48).
- Open Access
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
Proteins belonging to the Schlafen family are interferon-inducible and participate in the regulation of antiviral responses, immune signaling, and proteotoxic stress. Schlafen 11 (SLFN11) also kills cells with replicative damage, serving as a predictive biomarker for chemotherapeutic response. In this study, we examined SLFN11 expression and significance in multiple myeloma. The Cancer Genome Atlas and MMRF CoMMpass datasets were analyzed for SLFN11 expression. Bone marrow and cell lines samples were analyzed for SLFN11 protein. SLFN11-knockout multiple myeloma cell lines were used to explore how SLFN11 affects bortezomib (BTZ) response. Retrospective analysis of the HOVON-65/GMMG-HD4 phase III trial (n = 327) assessed clinical relevance. SLFN11 is consistently highly expressed across multiple myeloma subtypes (except CD1 and MAF/MAFB) and in normal plasma cells, and its expression strongly correlates with super-enhancer–driven plasma cell transcriptional programs. CD138-positive normal and myeloma plasma cells retain SLFN11 expression even when proliferative activity (MKI67/Ki-67) increases with disease progression. BTZ, a first-line multiple myeloma treatment, induces SLFN11 nucleolar translocation with suppression of ribosomal RNA (rRNA) synthesis. Knocking out SLFN11 in multiple myeloma cells enhances BTZ sensitivity and exatecan resistance, supporting SLFN11’s protective role in proteotoxic stress and sensitizing role in replication stress. In the HOVON-65/GMMG-HD4 trial, SLFN11-low patients seemed to preferentially benefit from BTZ-based therapy, suggesting that SLFN11 expression may guide therapeutic stratification in multiple myeloma.Significance:SLFN11 is highly expressed in normal and malignant plasma cells. BTZ induces SLFN11 nucleolar translocation, suppressing rRNA synthesis. SLFN11 confers BTZ resistance while sensitizing to topoisomerase I inhibitors. Low SLFN11 expression may identify patients more likely to benefit from BTZ-based therapy, providing a mechanistic rationale for SLFN11-guided therapeutic stratification.
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
Proteins belonging to the Schlafen family are interferon-inducible and participate in the regulation of antiviral responses, immune signaling, and proteotoxic stress. Schlafen 11 (SLFN11) also kills cells with replicative damage, serving as a predictive biomarker for chemotherapeutic response. In this study, we examined SLFN11 expression and significance in multiple myeloma. The Cancer Genome Atlas and MMRF CoMMpass datasets were analyzed for SLFN11 expression. Bone marrow and cell lines samples were analyzed for SLFN11 protein. SLFN11-knockout multiple myeloma cell lines were used to explore how SLFN11 affects bortezomib (BTZ) response. Retrospective analysis of the HOVON-65/GMMG-HD4 phase III trial (n = 327) assessed clinical relevance. SLFN11 is consistently highly expressed across multiple myeloma subtypes (except CD1 and MAF/MAFB) and in normal plasma cells, and its expression strongly correlates with super-enhancer–driven plasma cell transcriptional programs. CD138-positive normal and myeloma plasma cells retain SLFN11 expression even when proliferative activity (MKI67/Ki-67) increases with disease progression. BTZ, a first-line multiple myeloma treatment, induces SLFN11 nucleolar translocation with suppression of ribosomal RNA (rRNA) synthesis. Knocking out SLFN11 in multiple myeloma cells enhances BTZ sensitivity and exatecan resistance, supporting SLFN11’s protective role in proteotoxic stress and sensitizing role in replication stress. In the HOVON-65/GMMG-HD4 trial, SLFN11-low patients seemed to preferentially benefit from BTZ-based therapy, suggesting that SLFN11 expression may guide therapeutic stratification in multiple myeloma.Significance:SLFN11 is highly expressed in normal and malignant plasma cells. BTZ induces SLFN11 nucleolar translocation, suppressing rRNA synthesis. SLFN11 confers BTZ resistance while sensitizing to topoisomerase I inhibitors. Low SLFN11 expression may identify patients more likely to benefit from BTZ-based therapy, providing a mechanistic rationale for SLFN11-guided therapeutic stratification.
- Open Access
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
Bortezomib induces nucleolar recruitment of SLFN11 in multiple myeloma cells and doxycycline-inducible U2OS cells.
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
Bortezomib induces nucleolar recruitment of SLFN11 in multiple myeloma cells and doxycycline-inducible U2OS cells.
- Open Access
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
SLFN11 and MKI67 expression across cancer types and clinical parameters in multiple myeloma. A, Left, SLFN11 expression levels [log2(fpkm-uq + 1)] across various cancer types from the TCGA and MMRF datasets, with multiple myeloma (MM) showing the highest expression. Middle, SLFN11 expression in primary (newly diagnosed, n = 764) vs. recurrent (n = 80) bone marrow–derived CD138+ MM cells (P = 0.0034). Right, SLFN11 expression across disease stages using ISS/R-ISS criteria (P = 0.14). B, Left, MKI67 expression across cancer types, showing relatively low expression in MM. Middle, MKI67 expression in primary vs. recurrent CD138+ cells (P < 1 × 10−6). Right, MKI67 expression across disease stages, with stage III significantly higher than stage I (P < 1 × 10−4). C,SLFN11 expression (log2 intensity of probe 226743) across plasma cell disorders: NPCs (n = 22), MGUS (n = 44), SMM, (n = 12), and MM (n = 559; P = 0.17). This dataset (GSE5900/GSE2658) includes normal controls, which are not included in MMRF. D,SLFN11 expression across MM molecular subtypes (n = 559). CD1 and MF subtypes show significantly lower expression compared with the PR subtype (P < 1 × 10−4 and P = 0.036, respectively). E, Correlation between SLFN11 and CCND1 expression (r = −0.16, P = 2.3 × 10−6). Samples with low SLFN11 expression [log2(fpkm-uq + 1) < 2] predominantly exhibit high CCND1 expression. In all panels, bars represent mean values. ACC, adrenocortical carcinoma.
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
SLFN11 and MKI67 expression across cancer types and clinical parameters in multiple myeloma. A, Left, SLFN11 expression levels [log2(fpkm-uq + 1)] across various cancer types from the TCGA and MMRF datasets, with multiple myeloma (MM) showing the highest expression. Middle, SLFN11 expression in primary (newly diagnosed, n = 764) vs. recurrent (n = 80) bone marrow–derived CD138+ MM cells (P = 0.0034). Right, SLFN11 expression across disease stages using ISS/R-ISS criteria (P = 0.14). B, Left, MKI67 expression across cancer types, showing relatively low expression in MM. Middle, MKI67 expression in primary vs. recurrent CD138+ cells (P < 1 × 10−6). Right, MKI67 expression across disease stages, with stage III significantly higher than stage I (P < 1 × 10−4). C,SLFN11 expression (log2 intensity of probe 226743) across plasma cell disorders: NPCs (n = 22), MGUS (n = 44), SMM, (n = 12), and MM (n = 559; P = 0.17). This dataset (GSE5900/GSE2658) includes normal controls, which are not included in MMRF. D,SLFN11 expression across MM molecular subtypes (n = 559). CD1 and MF subtypes show significantly lower expression compared with the PR subtype (P < 1 × 10−4 and P = 0.036, respectively). E, Correlation between SLFN11 and CCND1 expression (r = −0.16, P = 2.3 × 10−6). Samples with low SLFN11 expression [log2(fpkm-uq + 1) < 2] predominantly exhibit high CCND1 expression. In all panels, bars represent mean values. ACC, adrenocortical carcinoma.
- Open Access
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
SLFN11 expression in cancer cell lines and multiple myeloma subtypes.
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
SLFN11 expression in cancer cell lines and multiple myeloma subtypes.
- Open Access
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
SLFN11 recruitment to nucleoli limits ribosomal RNA (rRNA) synthesis and affects global translation rates after Bortezomib treatment.
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
SLFN11 recruitment to nucleoli limits ribosomal RNA (rRNA) synthesis and affects global translation rates after Bortezomib treatment.
- Open Access
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
SLFN11/CD138 expression patterns and PCPI activity in sequential MM samples.
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
SLFN11/CD138 expression patterns and PCPI activity in sequential MM samples.
- Open Access
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 7 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
SLFN11 confers resistance to BTZ and sensitizes to TOP1 poisons. A, Time-course analysis of cell viability in WT and SLFN11 KO cells treated with BTZ. Left, KMS-34 cells treated with 2.5 or 5 nmol/L BTZ. Right, KMS-27 cells treated with 10 or 20 nmol/L BTZ. Cell viability was assessed by trypan blue exclusion at 0, 24, 48, 72, and 96 hours. B–D, Dose–response curves of WT and SLFN11 KO cells treated for 72 hours with BTZ (0–15 nmol/L; B), CPT (0–500 nmol/L; C) or exatecan (0–15 nmol/L for KMS-34, 0–50 nmol/L for KMS-27; D). Cell viability was measured using ATP assay. All experiments were performed in triplicate. Data are mean ± SD. *, P < 0.05; **, <0.01; ***, <0.001; ****, <0.0001.
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
SLFN11 confers resistance to BTZ and sensitizes to TOP1 poisons. A, Time-course analysis of cell viability in WT and SLFN11 KO cells treated with BTZ. Left, KMS-34 cells treated with 2.5 or 5 nmol/L BTZ. Right, KMS-27 cells treated with 10 or 20 nmol/L BTZ. Cell viability was assessed by trypan blue exclusion at 0, 24, 48, 72, and 96 hours. B–D, Dose–response curves of WT and SLFN11 KO cells treated for 72 hours with BTZ (0–15 nmol/L; B), CPT (0–500 nmol/L; C) or exatecan (0–15 nmol/L for KMS-34, 0–50 nmol/L for KMS-27; D). Cell viability was measured using ATP assay. All experiments were performed in triplicate. Data are mean ± SD. *, P < 0.05; **, <0.01; ***, <0.001; ****, <0.0001.
- Open Access
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
Heatmap of pathway-related genes and comprehensive GSEA analysis.
- 27 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
Heatmap of pathway-related genes and comprehensive GSEA analysis.